Health

Russian Firm to Build Insulin Plant in Pakistan

KARACHI: Russian pharmaceutical company Zavod Medsintez, in partnership with Pakistani firm Genetics Pharmaceuticals Private Limited, is set to invest approximately $80 million to establish insulin manufacturing facilities in Pakistan, sources confirmed on Monday.

The project will be executed in two phases. The first phase involves the construction of an aseptic filling plant dedicated to the handling and packaging of insulin products. This initial phase is projected to be completed by December 2028 with an estimated investment of $20 million.

Following this, the second phase will focus on the establishment of an active pharmaceutical ingredient (API) production plant. This phase carries a larger investment of around $60 million and aims to cover the entire production process — from API purification to the final packaging of insulin products. The second phase is expected to be finalized by December 2031. The development will also include technology transfer and the expansion into biotechnological products through the collaboration with C Biotech.

The initiative marks a significant advancement for Pakistan’s pharmaceutical sector, enabling local production of various insulin formulations, including Rosinsulin R, Rosinsulin C, and Rosinsulin M 30/70, which have been approved by the Drug Regulatory Authority of Pakistan (DRAP) for marketing within the country.

DRAP has declared that it will closely monitor the progress of the project and has mandated the submission of comprehensive, stage-wise investment timelines by the involved companies to ensure regulatory compliance and project transparency.

This development aligns with broader efforts to enhance healthcare infrastructure and pharmaceutical manufacturing capabilities in Pakistan, significantly reducing dependency on imports for insulin, a critical medicine for diabetic patients.

Related Stories

Leave a Reply

Your email address will not be published. Required fields are marked *